A Study to Evaluate the Efficacy and Safety of CBL-514 in Participants With Dercum's Disease Lipomas

Summary

This Phase 2 study will be an open-label and randomized study to assess the efficacy and safety of CBL-514 in participants with Dercum's Disease lipomas.

Timeline

Start

2022-10-03

Primary completion

2023-04-03

Completion

2023-04-03

Outcome

Met primary endpoint

release “CBL-514治療竇根氏症之二期臨床試驗（CBL-0201DD Phase 2, NCT05387733），並在ITT與PP統計族群所有療效指標皆達到統計顯著意義” caliwaybiopharma.com ↗

Drugs

Indications